Literature DB >> 7508973

Hepatitis C virus infection as a risk factor for non-alcoholic liver cirrhosis in Taiwan.

J F Tsai1, W Y Chang, J E Jeng, M S Ho, L Y Wang, M Y Hsieh, S C Chen, W L Chuang, Z Y Lin, J H Tsai.   

Abstract

To assess whether hepatitis C virus infection was a risk factor for the development of non-alcoholic liver cirrhosis, antibody to hepatitis C virus (anti-HCV; detected by a second generation HCV enzyme immunoassay), hepatitis B surface antigen (HBsAg; detected by radioimmunoassay) were tested in 150 cirrhotics and 150 sex-matched and age-matched healthy controls. The prevalence of anti-HCV and HBsAg in cirrhotics was higher than in controls (22.0%, 73.3% vs. 2%, 18.7%; P = 0.001). The prevalence of anti-HCV in HBsAg-negative cirrhotics (45.0%) was higher than that in HBsAg-positive patients (13.6%; P = 0.001). Both the anti-HCV and carriage of HBsAg were associated significantly with liver cirrhosis, showing odds ratio of 12.0 for HBsAg carriers and 13.8 for patients with anti-HCV. Compared with those without HBsAg and anti-HCV, there was a significantly positive linear trend for developing cirrhosis with the presence of HBsAg alone (odds ratio = 19.9), anti-HCV alone (odds ratio = 49.0), and those positive for HBsAg and anti-HCV (odds ratio = 81.8) (P = 0.00001). The population-attributable risk for developing liver cirrhosis was estimated as 10.8% for anti-HCV alone, 55.2% for HBsAg alone, and 9.4% for both anti-HCV and HBsAg in southern Taiwan. In conclusion, this study shows that hepatitis B and C virus infection act independently and synergistically in the development of non-alcoholic liver cirrhosis among Chinese in Taiwan.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7508973     DOI: 10.1002/jmv.1890410407

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  17 in total

1.  Liver cirrhosis in selected autoimmune diseases: a nationwide cohort study in Taiwan.

Authors:  Chien-Hsueh Tung; Ning-Seng Lai; Ming-Chi Lu; Ching-Chih Lee
Journal:  Rheumatol Int       Date:  2015-09-25       Impact factor: 2.631

2.  Liver cirrhosis as a real risk factor for necrotising fasciitis: a three-year population-based follow-up study.

Authors:  Tsung-Hsing Hung; Chen-Chi Tsai; Chih-Chun Tsai; Chih-Wei Tseng; Yu-Hsi Hsieh
Journal:  Singapore Med J       Date:  2014-07       Impact factor: 1.858

3.  Tumor necrosis factor-alpha 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma.

Authors:  Jen-Eing Jeng; Jung-Fa Tsai; Lee-Yea Chuang; Mei-Shang Ho; Zu-Yau Lin; Min-Yuh Hsieh; Shin-Chern Chen; Wan-Lung Chuang; Liang-Yen Wang; Ming-Lung Yu; Chia-Yen Dai; Jan-Gowth Chang
Journal:  Neoplasia       Date:  2007-11       Impact factor: 5.715

4.  Exploring the combined action of lifetime alcohol intake and chronic hepatotropic virus infections on the risk of symptomatic liver cirrhosis. Collaborative Groups for the Study of Liver Diseases in Italy.

Authors:  G Corrao; P Torchio; A Zambon; P Ferrari; S Aricò; F di Orio
Journal:  Eur J Epidemiol       Date:  1998-07       Impact factor: 8.082

5.  Urinary transforming growth factor α and serum α-fetoprotein as tumor markers of hepatocellular carcinoma.

Authors:  Jen-Eing Jeng; Meng-Feng Tsai; Hey-Ru Tsai; Lea-Yea Chuang; Zu-Yau Lin; Min-Yuh Hsieh; Shinn-Chern Chen; Wan-Lung Chuang; Liang-Yen Wang; Min-Lung Yu; Chia-Yen Dai; Jung-Fa Tsai
Journal:  Tumour Biol       Date:  2013-12-30

6.  Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: a prospective study.

Authors:  J F Tsai; J E Jeng; M S Ho; W Y Chang; M Y Hsieh; Z Y Lin; J H Tsai
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  Elevated urinary transforming growth factor-beta1 level as a tumour marker and predictor of poor survival in cirrhotic hepatocellular carcinoma.

Authors:  J F Tsai; J E Jeng; L Y Chuang; M L Yang; M S Ho; W Y Chang; M Y Hsieh; Z Y Lin; J H Tsai
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  Clinical evaluation of urinary transforming growth factor-beta1 and serum alpha-fetoprotein as tumour markers of hepatocellular carcinoma.

Authors:  J F Tsai; J E Jeng; L Y Chuang; M L Yang; M S Ho; W Y Chang; M Y Hsieh; Z Y Lin; J H Tsai
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  The risk of cellulitis in cirrhotic patients: a nationwide population-based study in taiwan.

Authors:  Ming-Nan Lin; Chen-Chi Tsai; Tsung-Hsing Hung; Chih-Chun Tsai
Journal:  Gut Liver       Date:  2012-10-18       Impact factor: 4.519

10.  Frequency of raised alpha-fetoprotein level among Chinese patients with hepatocellular carcinoma related to hepatitis B and C.

Authors:  J F Tsai; W Y Chang; J E Jeng; M S Ho; Z Y Lin; J H Tsai
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.